Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Epcoritamab in Relapsed/Refractory CLL/SLL
NCT05791409Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Apr 2024
- Primary completion
- Mar 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of epcoritamab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by HOVON. Primary endpoints: Recommended Phase II Dose and Undetectable Minimal Residual Disease at 29 months. Started Apr 2024; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05791409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05791409.